Marco Meglio

Resective epilepsy surgery was generally associated with good outcomes regarding employment status, seizure reduction, and antiseizure medication reduction.

In total, 65% of those who self-discontinued treatment experienced further seizure recurrence, which led to a majority (84%) of patients restarting treatment.

Despite good tolerability with few drug-related treatment emergent AEs and increased muscle volume, the failure to provide clinically relevant improvements in muscle function led to the discontinuation of ACE-083 for CMT in 2020.

If approved, ABBV-951 would become the first subcutaneous delivery of levodopa and carbidopa, the gold standard for symptom management in Parkinson disease.

At the end of the 12-month treatment period, interseizure cluster intervals increased from 14.8 days in the first period to 35.8 days in the final 90-day stretch.

A PK/PD model indicated that a higher concentration of nusinersen may predict an additional 5-point increase in CHOP-INTEND score beyond that observed with the approved 12-mg dose.

In preataxia individuals, serum neurofilament levels increased with proximity to predicted ataxia onset, with significant elevations already present 5 years before onset.

The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps to justify whether reflex tears are a reliable biomarker for Parkinson disease.

As of the cutoff date, median time to first hospitalization was not yet reached in the AMX0035 treatment group compared with 14.1 months in the group originally randomized to placebo.

When compared with healthy controls, patients with SMA type 3 performed worse on tests that assessed executive function, language, and visuospatial abilities, suggesting that intrinsic brain pathology may exist in these patients.

Confounders such as parental characteristics, sociodemographics, and pregnancy-specific factors led to an attenuated risk of seizures and epilepsy in children whose mothers were on SSRIs or SNRIs.

Since its approval for the treatment of medical refractory epilepsy in 2013, the closed-loop neuromodulation device has had its efficacy and safety confirmed in several pivotal studies and will now be assessed in focal epilepsy in the RESPONSE trial.

In a population of adults younger than 50 years with embolic stroke of undetermined source, despite repeated diagnostic workup at the time of recurrent stroke, no source of embolus was identified for two-thirds of participants with recurrent ischemic strokes.

Following the positive phase 3 findings, UCB plans to file regulatory submissions for both zilucoplan and rozanolixizumab later this year.

The chief executive officer of the Child Neurology Foundation discussed how her background in pediatric neurology will be used in a newly appointed NIH council position.

Those using riluzole concomitantly experienced even greater benefit from methylcobalamin, as demonstrated by increased differences in scores on ALSFRS-R vs placebo, suggesting the combination may be effective in ALS.

The biologics license application includes data from the pivotal phase 2b proof-of-concept trial, its open-label extension, and the ongoing phase 3 Clarity AD study, which includes almost 1800 participants.

Both fenfluramine dose groups showed significant decreases in generalized tonic-clonic seizures, whereas those on placebo showed worsening of their condition.

Across a 58-patient cohort, ravulizumab’s safety and tolerability were consistent with previous clinical studies, with most patients opting to enter a long-term extension period following the study.

Baseline cognition and function were highly correlated in those with mixed Alzheimer and Lewy body dementia pathologies, but not in pure Alzheimer disease nor pure dementia with Lewy bodies.

The combination of APOE ε4 carrier status with elevated blood pressure variability represented the fastest increase in phosphorylated tau levels over time.

In a prior phase 1b/2 study, BXCL501 demonstrated statistically significant reductions in agitation measures with both the 30- and 60-mcg doses as measured by multiple scales with no severe or serious adverse events.

The early-stage clinical trial will include 40 healthy volunteers to evaluate the safety and immune response of an investigational EBV gp350-Ferritin nanoparticle vaccine with a saponin-based Matrix-M adjuvant.

In latitudes lower than 40°, the underlying environmental determinants of MS severity reached saturation and a ceiling effect was observed, with no further systematic shift in the disease severity.

The findings in Alzheimer disease further elucidated the safety profile of AMX0035, as treatment emergent adverse events in the PEGASUS trial appeared to be largely disease driven.

The Parkinson’s Foundation will now partner with Morehouse School of Medicine, aiming to make the study and genetic testing more accessible for Black and African American persons in Atlanta.

Cerebrospinal fluid samples tested in a large cohort of patients at least 50 years of age with either mild cognitive impairment or Alzheimer disease showed high correlations between the Lumipulse G ß-Amyloid Ratio and PET status.

Vincent Martin, MD, president of the National Headache Foundation, provided insight on the ongoing challenges of treatment optimization for patients with chronic migraine.

Over the 36-month period of the FIREFISH study and its extension, treatment with risdiplam (Evrysdi; Genentech) resulted in decreased rate of adverse events, serious adverse events, and number of hospitalizations.

Using this new methodology, 78% of patients with progressive multiple sclerosis demonstrated large treatment benefits with the siponimod (Mayzent; Novartis) on at least 1 of 4 clinical outcomes.